8-K current report · filed Oct 6, 2026

Indivior Pharmaceuticals, Inc. (INDV) 8-K Current Report: October 6, 2026

Item 8.01INDV overview

Short answer

Indivior Pharmaceuticals, Inc. (INDV) filed an 8-K current report with the SEC on October 6, 2026 reporting Item 8.01 (Other Events). Merger proxy supplement filed October 6, 2026 after stockholder demand letters and two New York lawsuits alleging disclosure deficiencies.

Indivior Pharmaceuticals, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 8.01 · Other Events

  • Merger proxy supplement filed October 6, 2026 after stockholder demand letters and two New York lawsuits alleging disclosure deficiencies
  • Litigation risk remains a potential source of delay, despite Indivior and Supernus denying wrongdoing and voluntarily adding disclosures
  • Special stockholder meetings scheduled for October 15, 2026, making approval the immediate transaction catalyst
  • Revised advisor analyses incorporate Indivior’s approximately $500 million debt and $1 billion special dividend
  • Updated DCF ranges: Supernus $50.55 to $59.50 per share, Indivior $24.20 to $43.90 dividend-adjusted per share

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Indivior Pharmaceuticals, Inc. 8-K filings

Get the next INDV 8-K as it lands

Follow INDV for push alerts, or ask the research agent what this filing means.